Innovative NeuroTechnologies

Innovative NeuroTechnologies is a privately held, pre-clinical biotech firm pioneering novel anti-Tau therapies for Alzheimer's and other tauopathies. Operating with a virtual model to minimize overhead, the company is developing a proprietary dual intracellular and extracellular expression (dIEE) technology platform using AAV vectors to deliver anti-Tau antibodies. Led by founder Shawn Mojtahedian, Ph.D., INT has secured non-dilutive NIH SBIR grant funding and is pursuing an orphan drug strategy for specific tauopathies to potentially accelerate regulatory pathways. Its core thesis is that Tau is a more viable therapeutic target than beta-amyloid for modifying disease progression.

Dual Intracellular and Extracellular Expression (dIEE) technology using a recombinant AAV vector to deliver both an intracellular anti-Tau intrabody and a secreted extracellular anti-Tau antibody simultaneously to the CNS.

INT operates in the competitive Tau-targeting neurodegeneration space, competing with large pharma (e.g., Biogen, Eli Lilly) and other biotechs developing antibodies, small molecules, and gene therapies. Its differentiation lies in its dual intracellular/extracellular AAV-based approach. However, competitors have greater resources and more advanced clinical programs.